NCT05851261View on ClinicalTrials.gov

Study to Evaluate the Safety, Tolerance, Pharmacokinetics Characteristics of PA3670 Tablets in Chinese Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

60

Participants

Timeline

Start Date

April 13, 2023

Primary Completion Date

October 24, 2023

Study Completion Date

December 19, 2023

Conditions

Chronic HBV Infection

Interventions

DRUG

PA3670

Placebo as control

Trial Locations (1)

400010

The Second Affiliated Hospital of Chongqing Medical University, Chongqing

All Listed Sponsors

lead

Zhejiang Palo Alto Pharmaceuticals, Inc.

INDUSTRY